Amgen Victory In TKT Litigation Eases Pressure To Seek NESP Reimbursement

Amgen's victory in the erythropoietin patent infringement case against Transkaryotic Therapies takes some pressure off the company to seek reimbursement for its novel erythropoiesis stimulating protein Aranesp (darbepoetin alfa).

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet